Low objective response rates for patients with solid tumors have also been reported for other MDM2 inhibitors (Bauer et al., 2021; de Jonge et al., 2017; Stein et al., 2021; Wagner et al., 2017), while response rates for hematological malignancies like AML have been modestly higher for some agents studied (Erba et al., 2019; Konopleva et al., 2020; Stein et al., 2021). This evidence concerns the gene MDM2 and hematologic disorder.